Source: centralcharts

Press Release: Calliditas Therapeutics AB : Interim Report Q3, 2019

Interim Report Q3, 2019 Positive Regulatory Outcome - Enhanced study design PR Newswire STOCKHOLM, Nov. 14, 2019 STOCKHOLM , Nov. 14, 2019 /PRNewswire/ -- "This...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Renee Aguiar-Lucander's photo - CEO of Calliditas

CEO

Renee Aguiar-Lucander

CEO Approval Rating

90/100

Calliditas is a pharmaceutical company that develops and commercializes therapeutics for the treatment of inflammatory kidney diseases. Read more